FR2306697B1 - - Google Patents

Info

Publication number
FR2306697B1
FR2306697B1 FR7511154A FR7511154A FR2306697B1 FR 2306697 B1 FR2306697 B1 FR 2306697B1 FR 7511154 A FR7511154 A FR 7511154A FR 7511154 A FR7511154 A FR 7511154A FR 2306697 B1 FR2306697 B1 FR 2306697B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7511154A
Other languages
French (fr)
Other versions
FR2306697A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOGERAS
Original Assignee
SOGERAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOGERAS filed Critical SOGERAS
Priority to FR7511154A priority Critical patent/FR2306697A1/fr
Priority to GB22982/75A priority patent/GB1502182A/en
Priority to BE157011A priority patent/BE829845A/xx
Priority to LU72743A priority patent/LU72743A1/xx
Priority to CH800275A priority patent/CH603626A5/xx
Priority to NL7507441A priority patent/NL7507441A/xx
Priority to DE19752528360 priority patent/DE2528360A1/de
Priority to CA230,309A priority patent/CA1036597A/fr
Priority to ES439017A priority patent/ES439017A1/es
Priority to JP50080752A priority patent/JPS51118777A/ja
Priority to IT68679/75A priority patent/IT1036400B/it
Priority to US05/596,880 priority patent/US3984411A/en
Publication of FR2306697A1 publication Critical patent/FR2306697A1/fr
Application granted granted Critical
Publication of FR2306697B1 publication Critical patent/FR2306697B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR7511154A 1975-04-10 1975-04-10 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants Granted FR2306697A1 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR7511154A FR2306697A1 (fr) 1975-04-10 1975-04-10 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
GB22982/75A GB1502182A (en) 1975-04-10 1975-05-23 Pyrimidines
BE157011A BE829845A (fr) 1975-04-10 1975-06-04 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
LU72743A LU72743A1 (enExample) 1975-04-10 1975-06-16
CH800275A CH603626A5 (enExample) 1975-04-10 1975-06-19
NL7507441A NL7507441A (nl) 1975-04-10 1975-06-23 Werkwijze voor het bereiden van een geneesmiddel, zo gevormd geneesmiddel en werkwijze voor het be- reiden van daartoe geschikte geneeskrachtige ver- bindingen.
DE19752528360 DE2528360A1 (de) 1975-04-10 1975-06-25 Neue pyrimidine, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
CA230,309A CA1036597A (fr) 1975-04-10 1975-06-27 Pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
ES439017A ES439017A1 (es) 1975-04-10 1975-06-30 Un procedimiento para la preparacion de nuevas piridinas.
JP50080752A JPS51118777A (en) 1975-04-10 1975-06-30 Preparation method of new pyrimidine derivatives
IT68679/75A IT1036400B (it) 1975-04-10 1975-07-01 Pirimidine utilzzabili come prodotti antodiabetici ed ipolesterolici
US05/596,880 US3984411A (en) 1975-04-10 1975-07-17 Pyrimidines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7511154A FR2306697A1 (fr) 1975-04-10 1975-04-10 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants

Publications (2)

Publication Number Publication Date
FR2306697A1 FR2306697A1 (fr) 1976-11-05
FR2306697B1 true FR2306697B1 (enExample) 1979-08-10

Family

ID=9153719

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7511154A Granted FR2306697A1 (fr) 1975-04-10 1975-04-10 Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants

Country Status (12)

Country Link
US (1) US3984411A (enExample)
JP (1) JPS51118777A (enExample)
BE (1) BE829845A (enExample)
CA (1) CA1036597A (enExample)
CH (1) CH603626A5 (enExample)
DE (1) DE2528360A1 (enExample)
ES (1) ES439017A1 (enExample)
FR (1) FR2306697A1 (enExample)
GB (1) GB1502182A (enExample)
IT (1) IT1036400B (enExample)
LU (1) LU72743A1 (enExample)
NL (1) NL7507441A (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU176972B (hu) * 1977-06-13 1981-06-28 Gyogyszerkutato Intezet Sposob poluchenija novykh proizvodnykh piridazinil-gidrazona
US4648896A (en) * 1982-11-15 1987-03-10 Ciba-Geigy Corporation 2-aryl-4,6-dihalopyrimidines as antidote for protecting cultivated plants from phytotoxic damage caused by herbicides
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
ATE247104T1 (de) * 1997-11-05 2003-08-15 Neurosearch As Azaring-ether-derivate und ihre verwendung als nicotinic-ach-rezeptormodulatoren
ATE374766T1 (de) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
JP2006518763A (ja) * 2003-02-24 2006-08-17 アリーナ ファーマシューティカルズ, インコーポレイテッド グルコース代謝のモジュレーターとしてのフェニル−およびピリジルピペリジン誘導体
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2441775C (en) * 2003-09-23 2004-09-28 Westport Research Inc. Container for holding a cryogenic fluid
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
DK1931654T3 (da) * 2005-09-16 2009-07-27 Arena Pharm Inc Stofskiftemodulatorer og behandling af lidelser relateret dertil
TW200811147A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) * 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP5657383B2 (ja) 2007-08-30 2015-01-21 ダウ アグロサイエンシィズ エルエルシー 2−(置換フェニル)−6−アミノ−5−アルコキシ、チオアルコキシ、およびアミノアルキル−4−ピリミジンカルボキシラート、ならびに除草剤としてのそれらの使用
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US10934244B2 (en) 2015-06-15 2021-03-02 Nmd Pharma A/S Compounds for use in treating neuromuscular disorders
PT3310760T (pt) 2015-06-22 2022-11-10 Arena Pharm Inc Sal cristalino de l-arginina de ácido (r)-2-(7-(4-ciclopentil-3-(trifluorometil)benziloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para utilização em distúrbios associados a recetores de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259623A (en) * 1963-06-14 1966-07-05 Olin Mathieson Process for preparing 2-(secondary amino)-halogenopyrimidines
US3261833A (en) * 1964-10-20 1966-07-19 Smith Kline French Lab 2,4-diamino-6-aminoalkoxy pyrimidines
GB1143167A (en) * 1967-01-25 1969-02-19 Ucb Sa Derivatives of pyrimidine

Also Published As

Publication number Publication date
IT1036400B (it) 1979-10-30
CA1036597A (fr) 1978-08-15
CH603626A5 (enExample) 1978-08-31
BE829845A (fr) 1975-12-04
US3984411A (en) 1976-10-05
DE2528360A1 (de) 1976-10-21
NL7507441A (nl) 1976-10-12
JPS51118777A (en) 1976-10-18
LU72743A1 (enExample) 1975-10-08
FR2306697A1 (fr) 1976-11-05
ES439017A1 (es) 1977-06-16
GB1502182A (en) 1978-02-22

Similar Documents

Publication Publication Date Title
FR2306697B1 (enExample)
JPS5725450B2 (enExample)
JPS5337279B2 (enExample)
JPS51102895U (enExample)
JPS5323691Y2 (enExample)
JPS5352829Y2 (enExample)
JPS5624803Y2 (enExample)
JPS5518678Y2 (enExample)
JPS5649209B2 (enExample)
JPS51136528U (enExample)
JPS5287609U (enExample)
JPS51148233U (enExample)
JPS5284155U (enExample)
JPS5281069U (enExample)
JPS5276044U (enExample)
JPS522693U (enExample)
JPS5223279U (enExample)
JPS5221888U (enExample)
CH609231A5 (enExample)
BG23048A1 (enExample)
CH605596A5 (enExample)
DD119332A1 (enExample)
CH609915A5 (enExample)
CH609776A5 (enExample)
CH609709A5 (enExample)

Legal Events

Date Code Title Description
CD Change of name or company name
CD Change of name or company name
TP Transmission of property
ST Notification of lapse